GLP-1激动剂和肠道微生物组:一种双向关系
Srinivas Kamath1, Nicole S L Chan1, Paul Joyce1
1School of Pharmacy and Biomedical Science, Adelaide University, Adelaide, South Australia, Australia.
British journal of clinical pharmacology
|February 18, 2026
概括
葡萄糖类-1 (GLP-1) 受体激活剂对肠道细菌产生影响,而这些细菌反过来影响GLP-1分泌. 了解这种肠道微生物群相互作用是个性化糖尿病和肥胖治疗的关键.
科学领域:
- 药理学和代谢研究研究.
- 微生物组科学 微生物组科学
- 隐形生物学 隐形生物学
背景情况:
- 葡萄糖类-1 (GLP-1) 受体激动剂对于2型糖尿病 (T2DM) 和肥胖管理至关重要.
- 肠道微生物组在GLP-1动态和治疗反应中的作用是一个新兴的研究领域.
- 微生物代谢物影响GLP-1分泌,GLP-1激动剂调节肠道微生物的组成.
研究的目的:
- 审查目前关于GLP-1动态的微生物组介导调节的证据.
- 评估GLP-1激动剂的药物微生物组学效应.
- 概述未来的肠道微生物群-内蛋白轴接口的研究方向.
主要方法:
- 对GLP-1,肠道微生物群和代谢结果研究的文献综述.
- 对药物微生物组相互作用和多组组学数据的分析.
- 探索用于剖析宿主-微生物-药物轴的计算建模.
主要成果:
- 有证据表明,肠道微生物组与GLP-1信号传递之间的双向相互作用.
- 肠道微生物特征可能预测GLP-1激动剂反应的变异性.
- 微生物组的组成影响代谢结果超出了因克雷丁效应.
结论:
- 主体-微生物-药物轴对于理解GLP-1激动剂的作用至关重要.
- 个性化代谢医学可能利用微生物组环境优化GLP-1疗法.
- 未来的研究应该解决像饮食和宿主遗传学这样的混因素,以阐明引起机制.
相关概念视频
Glucagon-like Receptor Agonists
1.0K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.0K
What is Monogastric Digestion?
76.0K
The human body contains a monogastric digestive system. In a monogastric digestive system, the stomach only contains one chamber in which it digests food. Several other animal species also have monogastric digestive systems, including pigs, horses, dogs, and birds. This chapter, however, focuses on the human digestive system.
76.0K
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
1.1K
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
1.1K
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
615
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
615
Bacterial Flora of the Large Intestine
1.7K
The gut microbiome is formed by a vast and diverse community of bacteria that colonizes our large intestine. These bacteria start residing in the gut from birth and continue diversifying throughout life, influenced by factors such as diet, lifestyle, and stress. The gut bacterial community also includes bacteria from food and those that enter the colon through the anus.
The normal gut flora of the colon plays a critical role in generating essential vitamins such as vitamins K, B5, and B7.
The normal gut flora of the colon plays a critical role in generating essential vitamins such as vitamins K, B5, and B7.
1.7K
Drugs for Treatment of Constipation-Predominant IBS
915
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
915


